DNAtrix is a privately held biotech company developing virus-driven immunotherapies to treat cancer. Its proprietary adenovirus platform is based on an engineered version of the common cold virus that is designed to selectively infect and kill cancer cells while leaving healthy cells unharmed. The company’s lead product candidate is DNX-2401, which is expected to enter into a global pivotal Phase 3 clinical study for patients with recurrent glioblastoma. DNX-2401 is also being evaluated in a Phase 1 study for diffuse intrinsic pontine glioma, for which it has received FDA Fast Track and Rare Pediatric Disease designations. A second product candidate, DNX-2440, is entering a Phase 1 clinical study in patients with colorectal and other cancers with liver metastasis. The company’s investors include Morningside Ventures and Mercury Fund.
Location: United States, California, San Diego
Employees: 11-50
Total raised: $22M
Founded date: 2005
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 05.08.2016 | Grant | $2M | - |
| 14.10.2014 | Series B | $20M | - |
Mentions in press and media 13
| Date | Title | Description |
| 14.09.2021 | DNAtrix Announces the Appointment of David Liebowitz, M.D., Ph.D., as Chief Medical Officer | |
| 11.02.2021 | DNAtrix Announces Preclinical Data Demonstrating Anti-Tumor Activity of DNX-2401 in Models of Pediatric Tumors (AT/RT and CNS-PNET) Published in Clinical Cancer Research | |
| 20.11.2020 | DNAtrix Announces Positive Data from Phase 2 CAPTIVE (KEYNOTE-192) Study with DNX-2401 in Patients with Recurrent Glioblastoma Highlighted in an Oral Late-Breaking Presentation During Society for Neur... | |
| 09.11.2020 | DNAtrix Announces Multiple Data Presentations, Including Late-Breaking Phase 2 CAPTIVE (KEYNOTE-192) Data in Recurrent Glioblastoma, Planned for the Society for Neuro-oncology (SNO) Annual Meeting | |
| 24.10.2014 | Funding Roundup: Which biotech, medtech and healthIT startups got investments this week? | $4.1 million in equity raised of a proposed $10 million According to Phase IIa trials, its drug – levetiracetam – is showing promise in treating the mild cognitive decline that often results in Alzheimer’s. The drug’s usually used to treat ... |
| 14.10.2014 | DNAtrix Completes $20M Series B Round | SAN DIEGO, CA, Clinical-stage oncolytic immunotherapy company, announced that it has completed a $20M Series B equity financing. >> Click here for more funding data on DNAtrix >> To export DNAtrix funding data to PDF and Exc... |
| 14.10.2014 | DNAtrix Gets $20M For Cancer Killing Viruses | San Diego-based DNAtrix, which is developing modified viruses intended to treat aggressive cancers, has raised $20M in a Series B financing. The funding was led by Morningside Ventures, and also included Mercury Fund, Targeted Technology Fu... |
| 14.10.2014 | DNAtrix Completes $20M Series B Equity Financing | DNAtrix, a Houston, Texas and San Diego, California-based clinical-stage oncolytic immunotherapy company, completed a $20M Series B equity financing. The round was led by new investor Morningside Ventures with participation from existing in... |
| 16.01.2014 | Potential to improve delivery of drugs directly into the brain nets Boston-area device firm $4M | While some pharmaceutical and medical device companies are working on ways to penetrate the barrier, Alcyone’s devices are based on a way of circumventing it. They build on a drug delivery modality called convection-enhanced delivery, where... |
| 17.08.2012 | Brain cancer therapy that kills tumor cells with an adenovirus heads for phase 2 trial | Initially, the drug is being studied in high-grade gliomas, brain tumors that are rarely curable even with surgery, radiation and chemotherapy. Tufaro said the company saw “tremendous efficacy” in its phase 1 study conducted at MD Anderson ... |
Show more